. . "RIV/00023736:_____/10:00008797" . "3" . "Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies"@en . "293274" . . . "1"^^ . "1"^^ . "P(LC06044), Z(MZ0UHKT2005)" . . . "3" . "[BABB4FE9BF12]" . "25"^^ . "Current Molecular Pharmacology" . . "Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies" . "AE - St\u00E1t Spojen\u00E9 arabsk\u00E9 emir\u00E1ty" . . . "1874-4672" . . . "Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies." . "hematological malignancies; NF-kappaB; NF-kappaB inhibitors; proteasome inhibitors"@en . . . "Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies"@en . "Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies."@en . . "Fuchs, Ota" . . "Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies" . . . . "RIV/00023736:_____/10:00008797!RIV12-MZ0-00023736" .